|
|
|
|
|
Legal status
Patent revoked (after opposition at EPO)
| (51) | INT.CL. | A61K 31/454 | (2006.01) |
| A61K 31/4985 | (2006.01) | ||
| A61K 31/7056 | (2006.01) | ||
| A61P 31/22 | (2006.01) |
| (11) | Number of the document | 2968302 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14725812.3 |
| Date of filing the European patent application | 2014-03-14 | |
| (97) | Date of publication of the European application | 2016-01-20 |
| (45) | Date of publication and mention of the grant of the patent | 2017-09-06 |
| (46) | Date of publication of the claims translation | 2017-12-27 |
| (86) | Number | PCT/US2014/027556 |
| Date | 2014-03-14 |
| (87) | Number | WO 2014/152635 |
| Date | 2014-09-25 |
| (30) | Number | Date | Country code |
| 201361783437 P | 2013-03-14 | US |
| (72) |
BERNSTEIN, Barry M., US
DUTTA, Sandeep, US
LIU, Wei, US
PODSADECKI, Thomas J., US
CAMPBELL, Andrew L., US
MENON, Rajeev M., US
LIN, Chih-Wei, US
WANG, Tianli, US
AWNI, Walid M., US
MENSING, Sven, DE
|
| (73) |
AbbVie Inc.,
1 North Waukegan Road, North Chicago, IL 60064,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Tiesioginio poveikio antivirusinių agentų ir ribavirino derinys, skirtas HVC sergančių pacientų gydymui |
| COMBINATION OF DIRECT ACTING ANTIVIRAL AGENTS AND RIBAVIRIN FOR TREATING HCV PATIENTS |
| Payment date | Validity (years) | Amount | |
| 2020-03-05 | 7 | 162.00 EUR |
| Patent revoked (after opposition at EPO) | ||
| Invalidation date | 2020-09-01 |